The funding round was led by Sequoia Capital’s Sequoia India and MassMutual Ventures, with additional funding from Openspace Ventures, Aviva Ventures, SGInnovate, Chinese online healthcare platform Jianke and the investment arm of the Singapore government’s Economic Development Board.
Biofourmis combines AI, a patient-facing mobile app and FDA-approved wearable biosensors to ensure adherence to medication regimens, suggest therapeutic interventions and predict and prevent adverse reactions. The platform and pipeline have so far been optimized for patients with complex chronic conditions such as heart failure, acute coronary syndrome, chronic obstructive pulmonary disease and chronic pain.
More articles about AI:
Alegeus unveils AI-powered HSA platform
Study: Google AI outperforms radiologists in diagnosing lung cancer
Facebook CTO admits AI may not be the panacea he believed it was
